Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Interim Report 3 2022/23
Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.
Clarification Regarding Potential Collaborations
Thi information is provided to mitigate any misinterpretation of the information unintentionally made publicly after a PHI presentation at a CERN Knowledge Transfer Seminar held on March 27, 2023.
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.
CERN seminar: The Promise of Regenerative Medicine and AI
During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
Technological developments in the rapidly evolving field of live-cell microscopy
Discover more about the developments in live-cell microscopy and how the HoloMonitor® technology is a gentle time-lapse imaging method for non-invasive, long-term and quantitative analysis of living cells.
BioStock: PHI catches eye of major investor
BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Swiss-based Altium acquires major stake in PHI
PHI announces that Altium S.A. recently acquired Formue Nord’s entire holdings in PHI of 2 416 679 shares and 1 491 362 TO 3 warrants and committed to exercise the obtained warrants.
The Scientist: Observing Cells in Their Natural State with Digital Holographic Cytometry
New blog article: Head over to The Scientist to read about observing cells in their natural state with digital holographic cytometry.
BioStock: PHI comments on the new senior positions in the company
BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.